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NEW PERSPECTIVES IN PULMONOLOGY
Long-term  oxygen  therapy  (LTOT) revisited:  In defense
of non-delivery  LTOT  technology
Oxigenoterapia  de  longa  durac¸ão (OLD)  revista:  Em  defesa
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The  term  ‘‘non-delivery  LTOT’’ is  used  to  describe  installa-
tions  of  newer  home  oxygen  therapy  systems  where  oxygen
concentrator  technology  is  used  to  provide  both  station-
ary  and  ambulatory  oxygen.1 The  use  of  non-delivery  LTOT
equipment  obviates  the  need  for  oxygen  supply  companies
to  make  repeat  (and  costly)  home  deliveries  to  replenish
depleted  gaseous  or  liquid  oxygen  contents,  the  majority  of
which  is  most  often  used  during  ambulation  away  from  the
stationary  system.
The  evidence  base  for  LTOT  supports  the  use  of  both
stationary  and  ambulatory  oxygen  systems  to  maintain  ade-
quate  oxygenation  at  all  times  and  under  all  conditions  of
use.1,2 Non-delivery  LTOT  systems  therefore  offer  hypoxemic
COPD  patients  requiring  continuous,  uninterrupted  supple-
mental  oxygenation,  and  meaningful,  real-time  options.
With  a  properly  functioning  non-delivery  system,  LTOT  users
now  have  the  option  of  spontaneously  going  where  they  want
to  go,  when  they  want  to  go,  and  how  they  want  to  go,
as  opposed  to  constantly  waiting  (and  hoping)  that  a much
needed  re-supply  delivery  will  take  place  as  scheduled.
There  are  three  options  presently  available  to  provide
non-delivery  LTOT.1 One  method  is  to  use  a  standard  station-
ary  oxygen  concentrator,  in  tandem  with  a  pressure  booster,
to  re-ﬁll  small  portable  cylinders.  A  second  option  is  the  use
of  a  portable  oxygen  concentrator  (POC).  The  third  option,
still  under  development,  is  a  standard  oxygen  concentrator,
used  in  tandem  with  a  cryogenic  liqueﬁer,  to  re-ﬁll  a  small
canister  with  liquid  oxygen.  All  three  options  employ  the  use
of  concentrated  oxygen  (≈93%)  as  opposed  to  medical  grade
oxygen  (99.9%).
All  of  the  aforementioned  non-delivery  systems  incorpo-
rate  the  pulse  dose  delivery  of  oxygen.  With  pulse  dose
delivery,  a  preset  volume  (or  bolus)  of  oxygen  is  admin-
istered  at  some  point  during  the  inspiratory  phase  of  a
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atient’s  breathing  cycle.  In  this  regard,  pulse  dose  deliv-
ry  devices  provide  an  intermittent  ﬂow  (IF)  of  oxygen  as
pposed  to  the  more  ubiquitous  continuous  ﬂow  (CF)  deliv-
ry.  Oxygen  administered  with  an  IF  device  is  quantiﬁed  in
illiliters  (mL)  per  breath  while  the  standard  for  CF  is  liters
er  minute  (L/min).
In  theory,  the  ability  to  adjust  the  size  of  a  delivered
ulse  volume  of  oxygen,  as  well  as  the  speed  at  which
he  selected  pulse  dose  volume  will  be  delivered,  should
acilitate  optimum  oxygenation.  This  is  especially  desir-
ble  during  the  periods  of  even  moderate  ambulation  when
ystemic  oxygen  demand  increases.3 It  should  be  noted
hat  pulse  volume  dosing  was  originally  developed  to  con-
erve  gaseous  or  liquid  contents  of  smaller  portable  units.4
hile  this  original  oxygen  conservation  application  is  still
alid  when  used  with  home  re-ﬁlled  gaseous  or  liquid  cylin-
ers,  when  integrated  into  a  POC,  the  IF  function  is  to
rolong  battery  life.  This  raises  important  questions  about
he  accuracy  of  oxygen  dosing  when  a  POC  is  used  as  a
on-delivery  LTOT  system,  although  evidence  suggests  that
imilar  issues  surround  the  use  of  traditional  oxygen  con-
erving  devices.5--7
There  are  two  classes  of  POCs  --  those  that  can  only
perate  in  the  pulse  dose/IF  mode  (single-mode  POCs),  and
hose  capable  of  operating  in  both  the  pulse  dose/IF  mode
nd  CF  mode  (dual-mode  POCs).  On  average,  single-mode
OCs  weigh  ≤  4.5  kg,  whereas  dual-mode  POCs  weigh  slightly
ore,  ≈7.7  kg.  The  trade-off  with  the  lighter  weight  single-
ode  POCs  is  a  reduction  in  the  amount  of  concentrated
xygen  that  can  be  produced.  Where  single-mode  POCs  pro-
uce  approximately  700--900  mL  of  concentrated  oxygen  per
inute,  dual-mode  POCs  are  capable  of  producing  up  to
000  mL  per  minute.  The  larger  oxygen  production  capabil-
ty  of  dual-mode  POCs  provides  prescribers  and  home  care
linicians  more  options  while  individually  titrating  chronic
ypoxemic  patients  to  a  target  arterial  oxygen  saturation.1
All  POCs  (single  and  dual  mode)  share  the  common  fea-
ure  of  operating  from  ﬂexible  power  sources,  i.e.  standard
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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ousehold  electrical  outlet,  the  external  power  outlet  in
otor  vehicles  and  aircraft,  or  a  rechargeable  battery.  When
ome  oxygen  patients  ﬁrst  learn  about  POCs,  especially
atients  using  a  CF  delivery  device,  they  are  quickly  enam-
red  with  the  lightweight  feature  of  most  single-mode  POCs.
he  most  attractive  feature  is  the  potential  ability  to  use  a
--4  kg,  easily  carried  device  that  is  literally  self-contained,
llowing  the  device  to  be  used  for  both  stationary  and
mbulatory  purposes.  However,  many  soon  discover  that
he  reduced  oxygen  production  per  minute  (the  trade-off
or  the  device’s  lighter  weight)  is  insufﬁcient  to  prevent
esaturation  at  all  times  and  under  all  conditions,  especially
uring  extended  ambulation.  A  recent  report  also  showed
he  inability  of  a  pulse  dose/IF  POC  to  be  used  in  conjunc-
ion  with  noninvasive  ventilation  to  provide  supplemental
xygen.8
At  the  root  of  the  problem  is  the  widely  held  misper-
eption  that  a  numerical  setting  on  a  pulse  dose/IF  device
s  equivalent  to  the  corresponding  continuous  ﬂow  -- e.g.  a
umerical  setting  of  1,  2  or  3  is  equal  to  1,  2  or  3  L/min.  This
s  not  the  case  and  often  results  in  unintended  sub-optimal
osing.  It  is  intuitive  that  the  exact  dose  of  any  medication
rescribed  for  long-term  control  of  a  chronic  medical  condi-
ion  (e.g.  hypertension,  hyperlipidemia,  hyperglycemia)  be
nown.  This  truism  applies  equally  when  oxygen  is  used  as
 controller  medication  for  chronic  hypoxemia.  Failure  to
now  the  dose  of  any  delivered  medication  is  not  conducive
o  attainment  of  optimum  clinical  outcomes  or  sustained
ymptom  control.  With  respect  to  sub-optimal  LTOT  dosing,
he  inability  to  correct  underlying  severe  chronic  hypoxemia
ften  leads  to  a  worsening  of  the  deadly  adverse  sequelae
f  COPD.9
Regardless  of  which  type  of  POC  is  used,  when  operat-
ng  in  the  pulse  dose/IF  mode,  the  amount  of  the  oxygen
ulse  volume  (in  mL)  must  be  known  for  each  numerical  set-
ing.  It  is  also  essential  to  know  the  delivered  oxygen  purity
t  a  particular  setting,  as  well  as  the  effect  an  increase
n  the  breathing  rate  would  have  on  the  delivered  oxy-
en  purity.  For  example,  some  single-mode  POC  models,
hen  set  on  the  device’s  maximum  setting,  may  well  deliver
xygen  purity  ≥  90%  at  a  breathing  rate  of  12  breaths/min,
nly  to  have  the  oxygen  purity  decrease  into  the  mid  80%
ange  when  the  breathing  rate  increases  to  20  breaths/min
r  higher.  In  this  all-too  common  example,  the  patient’s
equirements  exceed  the  performance  capability  of  the
elected  POC.  A  decrease  in  oxygen  purity  typically  results
n  periods  of  unintended  arterial  desaturation,  and  may  lead
o  the  incorrect  perception  that  the  disease  state  is  deterio-
ating,  when  in  fact,  it  is  the  LTOT  equipment  that  is  failing
he  patient.10
Regrettably,  not  all  manufacturers  promoting  POCs  for
on-delivery  purposes  provide  detailed  information  regard-
ng  the  pulse  dose  volume  (expressed  in  mL)  of  a  particular
elivery  device  at  a  speciﬁc  setting.  Equally  frustrating  is  the
bsence  of  information  on  the  impact  of  increased  breathing
ates  on  concentrated  oxygen  purity  at  each  setting.  Fur-
her,  there  is  no  consistency  in  the  number  of  numerical
ettings  a  particular  device  may  have.  Some  models  have
hree  settings  (i.e.  1,  2,  and  3)  whereas  others  have  ﬁve
ettings,  and  some  even  six  or  more.  Adding  further  confu-
ion  is  the  fact  that,  in  most  cases,  the  selected  setting  does
ot  display  the  delivered  pulse  volume.  Thus,  one  modelNEW  PERSPECTIVES  IN  PULMONOLOGY
OC  will  deliver  a  pulse  volume  of  27  mL  at  the  highest  set-
ing  of  3,  whereas  a  competing  model  will  deliver  a  pulse
olume  of  192  mL  at  the  highest  setting  of  9.  The  former
xample  is  characteristic  of  single-mode  POCs  whereas  the
atter  is  characteristic  of  the  more  robust  dual-mode  POCs.
n  the  absence  of  uniform  data  on  performance  speciﬁca-
ions,  especially  with  single-mode  POCs,  the  only  way  to
nsure  adequate  oxygenation  is  to  conduct  an  individual-
zed  titration  study  and  equip  the  patient  with  a  personal
ulse  oximeter.11
While  appealing  in  concept,  because  of  the  aforemen-
ioned  deﬁciencies,  it  must  be  understood  that  non-delivery
echnology  is  not  for  every  LTOT  user.  While  there  may
e  those  who  cannot  be  adequately  saturated  with  one
odel  of  single-mode  POC,  another  brand  single-mode  POC
ith  higher  oxygen  production  capabilities  might  work.
t  the  same  time,  there  may  those  patients  in  whom  no
ingle-mode  POC  will  work,  but  who  can  attain  satisfactory
xygenation  with  a  dual-mode  POC.  It  is  therefore  incum-
ent  for  both  prescribers  of  LTOT  and  home  care  clinicians  to
nderstand  the  capabilities  and  limitations  of  non-delivery
TOT  systems.  It  is  this  writer’s  experience  that  this  is  the
xception  rather  than  the  rule.  Accordingly,  it  is  highly  rec-
mmended  that  patients  having  any  type  of  pulse  dose/IF
evice  prescribed  for  any  use  need  a  titration  study  to  deter-
ine  the  device’s  ability  to  maintain  adequate  oxygenation
nder  all  conditions  of  intended  use.2,12,13
In  summary,  when  used  correctly  by  knowledgeable  pre-
cribers,  home  care  clinicians  and  properly  trained  patients,
on-delivery  LTOT  systems  can  provide  a  welcome  alterna-
ive  to  being  tethered  to  a  large,  stationary  LTOT  device,
his  in  spite  of  the  aforementioned  performance  limita-
ions.  Technological  advances  are  sure  to  result  in  higher
xygen  production  capability  of  POCs  even  as  unit  weight
ecreases.  Also  on  the  horizon  is  the  presumable  integration
f  closed-loop,  oximetry-driven  oxygen  delivery  technology
here  oxygen  dosing  is  automatically  adjusted  to  main-
ain  a  target  arterial  saturation.13-15 As  non-delivery  LTOT
echnology  does  continues  to  evolve,  one  hopes  that  the
ppropriate  regulatory  agencies  will  establish  uniform  stan-
ards  in  terms  of  equipment  labeling,  dosing  representations
nd  performance  capabilities  to  redress  the  issues  and  con-
erns  described  herein.
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